The ubiquitin ligase CHIP modulates cellular behaviors of gastric cancer cells by regulating TRAF2

Abstract

Background CHIP is an E3 ubiquitin ligase that plays contrast roles in diverse human malignancies, depending on its targets. To date, the mechanisms underlying the function of CHIP in gastric cancer remains unclear. Here, we aim to further clarify the effects of CHIP on the development and progression of gastric cancer and explore its potential target. Methods Stably transfected CHIP-shRNA and TRAF2-shRNA AGS gastric cancer cell lines were established using Lipofectamine 2000. Cell growth was measured by an xCelligence real-time monitoring system and colony formation assay. Cell proliferation was detected using CCK-8, Ki-67, or CFSE assays. Apoptosis was detected by TUNEL assay or Annexin V/PI-staining followed by flow cytometric analysis. Cell cycle distribution was detected by PI-staining followed by flow cytometric analysis. Cell migration and invasion abilities were measured by a real-time xCelligence system, Transwell insert, and scratch assays. The expression of cell cycle-related proteins, apoptosis-related proteins, AKT, ERK, NF-κB signaling subunits, MMP2, MMP9, and Integrin β-1 were detected by Western blotting analysis. NF-κB DNA-binding capability was quantified using an ELISA-based NF-κB activity assay. Gastric cancer tissue microarray was analyzed to investigate the expression of both CHIP and TRAF2, and their clinical significance. Results The CHIP-silencing in the AGS cells was oncogenic evidenced by the appearance of capable of anchorage-independent growth. The CHIP-silencing significantly enhanced the AGS cell proliferation capability likely due to the induced phosphorylation of ERK. The CHIP-silencing significantly inhibited apoptosis due to increased expression of Bcl-2. The CHIP-silencing promoted the AGS cell migration and invasion abilities, likely by regulating the expression of Integrin β-1. TRAF2 expression was markedly decreased in the CHIP-overexpressing cells at protein level, but not at mRNA level. The TRAF2-silencing markedly inhibited the proliferation ability of the AGS cells, the defected cell proliferation and enhanced apoptosis were involved in. The TRAF2-silencing also attenuated the cell migration and invasion capacities of the AGS cells. Furthermore, the expression of CHIP was downregulated while the expression of TRAF2 was upregulated in gastric cancer tissues. TRAF2 expression is independent prognostic factors of gastric cancer. The expression of CHIP and TRAF2 was negatively correlated in the gastric cancer tissue. Lower CHIP or higher TRAF2 was significantly linked to shorter overall survival in gastric cancer patients. Conclusions TRAF2 influenced diverse aspects of cellular behavior of gastric cancer cells, including cell growth, migration, and invasion, which was in contrast to the functions of CHIP. TRAF2 could be considered as an independent prognostic factor in gastric cancer patients. It is possible that TRAF2 was a substrate of CHIP and CHIP regulated the TRAF...

Comprehensive Characterization of Tumor Purity and Its Clinical Implications in Gastric Cancer

“…Gastric cancer (GC) is the fifth most prevalent cancer and the third most frequent cause of cancer-related deaths worldwide ( Bray et al, 2018 ), with almost 1,000,000 new cases and 800,000 deaths each year ( Torre et al, 2015 ; Bray et al, 2018 ). Owing to a lack of symptoms in the early stage, most patients with GC are usually diagnosed at an advanced stage ( Dai et al, 2019 ). Treatment options for patients at an advanced stage are limited, resulting in a relatively low 5-year survival rate (<20%) ( Katai et al, 2018 ).…”

Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses

“…Gastric cancer (GC) is the third leading cause of cancer-related mortality and the fifth most frequently diagnosed malignancy worldwide ( 1 ), with almost 1,000,000 estimated new cases and 800,000 deaths each year ( 1 , 2 ). Due to the lack of early symptoms, most patients with GC are usually diagnosed at an advanced stage ( 3 ). Despite effective treatment, relapse and metastasis are common in advanced GC, causing a fairly low 5-year survival rate (<20%) ( 4 ).…”

miR-671-5p Inhibition by MSI1 Promotes Glioblastoma Tumorigenesis via Radioresistance, Tumor Motility and Cancer Stem-like Cell Properties

“…Moreover, we found that TRAF2 overexpression significantly rescued the migration ability in the presence of miR-671-5p (54.0 ± 7.0 vs. 21.0 ± 3.0, p = 0.00401). Although TRAF2 has less evidence in the GBM, there are several reported supporting that TRAF2 associated with migration of gastric cancer cells by regulating TRAF2 [ 24 ]. Overall, we concluded that MSI1 maintains EMT properties by inhibiting the miR-671-5p/TRAF2 axis.…”